What's Happening?
At the American Association for Cancer Research's annual meeting, Moderna presented promising early results from a Phase 2 trial of its investigational antigen therapy, mRNA-4359, in combination with Merck's immunotherapy Keytruda. This combination is being
tested as a first-line treatment for locally advanced and metastatic melanoma. As of December 1, 2025, the trial showed an overall response rate of 83%, with two out of twelve patients achieving a complete response and eight having a partial response. Moderna's Chief Development Officer, David Berman, highlighted the novel dual mechanism of mRNA-4359, which activates T cells to kill cancer cells and recalibrates the tumor microenvironment to a more immune-favorable state. The trial's results are considered a promising signal, although the small patient sample size means it may not yet garner significant investor enthusiasm.
Why It's Important?
The development of effective combination therapies is crucial in cancer treatment, as they can target tumor cells more efficiently while reducing side effects and drug resistance. The promising results from Moderna's trial could lead to new treatment options for melanoma, a cancer that can be challenging to treat. If successful, this combination therapy could improve survival rates and quality of life for patients with advanced melanoma. The trial's success also underscores the potential of mRNA technology in oncology, expanding its application beyond vaccines to therapeutic areas. This could pave the way for further innovations in cancer treatment, benefiting patients and potentially leading to new market opportunities for pharmaceutical companies.
What's Next?
Moderna plans to continue expanding the trial to determine if mRNA-4359 provides additional activity in patients who have progressed on checkpoint inhibitors. The company aims to gather more data over the next year to support the therapy's efficacy. If the results remain positive, Moderna may seek FDA Fast Track designation for the combination therapy in melanoma, which could expedite its development and approval process. This would allow the treatment to reach patients more quickly, potentially improving outcomes for those with limited options. The broader implications for mRNA technology in cancer treatment could also lead to increased investment and research in this area.
